Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Minerva Neurosciences (NERV) Operating Expenses (2016 - 2026)

Minerva Neurosciences filings provide 2 years of Operating Expenses readings, the most recent being $21.4 million for Q4 2021.

  • On a quarterly basis, Operating Expenses rose 192.86% to $21.4 million in Q4 2021 year-over-year; TTM through Dec 2021 was $45.4 million, a 15.35% increase, with the full-year FY2025 number at $15.1 million, down 30.87% from a year prior.
  • Operating Expenses hit $21.4 million in Q4 2021 for Minerva Neurosciences, up from $7.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $21.4 million in Q4 2021 to a low of $7.3 million in Q4 2020.